Table 1.
Clinical data of the patients enrolled in the study.
| Sample ID | Tissue Biopsy | Sidedness of the Primary Tumour | Number and Location of Metastatic Sites | First-Line Treatment |
|---|---|---|---|---|
| 1 |
KRAS G12D |
descending colon | 2 (liver, lung) | FOLFOX + BEVA |
| 2 |
BRAF V600E |
ascending colon | 3 (stomach, peritoneum, lymph nodes) | Not applicable: performance status deterioration |
| 3 | wt | sigmoid colon | 1 (lung) | FOLFOX + PANI |
| 4 | wt | sigmoid colon | 2 (liver, lymph nodes) | FOLFOXIRI + PANI |
| 5 | wt | sigmoid colon | 1 (liver) | FOLFOX + PANI |
| 6 | wt | rectum | 2 (lung, liver) | FOLFOX + BEVA |
| 7 | wt | splenic flexure, sigmoid colon-rectum | 1 (liver) | FOLFOX + PANITUMUMAB |
| 8 | wt | descending colon | 1 (peritoneum) | FOLFIRI + CETUXIMAB |
| 9 | wt | ascending colon | 2 (lung, liver) | CAPECITABINA |
| 10 | wt | rectum | 1 (lung) | FOLFIRI + CETUXIMAB |
| 11 | wt | sigmoid colon | 2 (liver, peritoneum) | FOLFOX + CETUXIMAB |
| 12 | wt | transverse colon | 1 (liver) | FOLFOX + PANI |
| 13 |
KRAS A146T |
descending colon | 3 (liver, peritoneum, lymph nodes) | XELOX + BEVA |
| 14 |
KRAS G13D |
sigmoid colon | 2 (liver, lymph nodes) | FOLFOX + BEVA |
| 15 | wt | descending colon | 1 (liver) | FOLFOX + CETUXIMAB |
| 16 |
KRAS A146T |
cecum | 2 (right iliac bone, muscles) | XELOX+BEVA |
| 17 | wt | cecum, rectum | 1 (peritoneum) | FOLFOX + PANITUMUMAB |
| 18 |
KRAS G12D |
hepatic flexure | 1 (liver) | FOLFOX+BEVACIZUMAB |
| 19 |
KRAS G12S |
descending colon | 1 (liver) | FOLFOX+BEVACIZUMAB |
| 20 |
KRAS G12D |
rectum | 1 (liver) | FOLFOX+BEVACIZUMAB |